MedPage Today: Single-Dose Dolutegravir Safe in Kids With HIV Receiving Preventive TB Treatment

25 February 2026

MedPage Today news story

Children with HIV on dolutegravir-based antiretroviral therapy can safely receive the standard prophylactic TB treatment without needing to up their dolutegravir dose, the phase I/II DOLPHIN-KIDS study suggested.

Among 41 children who received a single dose of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) and the standard TB treatment of rifapentine and isoniazid, 95% remained virally suppressed and dolutegravir trough concentrations dropped below the predetermined threshold of 64 ng/mL in only two children, researchers reported at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI 2026).

Read the full news story here.

Source: MedPage Today